Meta-analysis: The outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 4, 2008, Pages 397-404

  Andriulli, A ^a   Mangia, A ^a   Iacobellis, A ^a   Ippolito, A ^a   Leandro, G ^b   Zeuzem, S ^c  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG DOSE REGIMEN; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS 2; HEPATITIS C VIRUS 3; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RAPID VIROLOGICAL RESPONSE; SHORT COURSE THERAPY; SUSTAINED VIROLOGICAL RESPONSE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VIREMIA;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 47749115740     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03763.x     Document Type: Article

References (19)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001 358 : 958 65.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
3. Hadziyannis SJ, Sete H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 55.
4. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004 40 : 993 9.
5. HCV Meta-Analysis Working Group. Efficacy of Peg-IFN alfa-2b vs. Peg-IFN alfa-2a + ribavirin regimens in treatment-naïve chronic HCV patients: a cumulative meta-analysis of retrospective data from 6 clinic sites. Hepatology 2005 42 (Suppl. 1 671A.
6. Rizzetto M. Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirin. J Hepatol 2005 42 : 275 8.
7. Dalgard O, Bjøro K, Hellum KB, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004 40 : 1260 5.
8. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005 352 : 2609 17.
9. Von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha 2a (40 KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005 129 : 522 7.
10. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007 357 : 124 32.
11. Brown R, Jacobson I, Afdhal N, et al. Differences in treatment outcome to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the WIN-R trial. Gastroenterology 2006 130 : A767.
12. Meyer-Wyss B, Rich P, Egger H, et al. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 μg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat 2006 13 : 457 65.
13. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004 127 : 1724 32.
14. Andriulli A, Dalgard O, Bjoro K, Mangia A. Short-term treatment duration for HCV-2 and HCV-3 infected patients. Dig Liv Dis 2006 38 : 741 8.
15. Dalgard O, Bjøro K, Ring-Larsen H, et al. A randomized controlled trial of pegylated interferon alfa and ribavirin for 14 vs 24 weeks in patients with HCV genotype 2 or 3 and rapid virological response. Hepatology 2008 47 : 35 42.
16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 17 : 1 12.
17. Hasselblad V, McCrory D. Meta-analytic tools for medical decision making: a practical guide. Med Decis Making 1995 15 : 81 96.
18. Klein S, Simes J, Blackburn GL. Total parenteral nutrition and cancer clinical trial. Cancer 1986 58 : 1378 86.
19. Leandro G. Meta-analysis in Medical Research. Oxford, UK : Blackwell Publishing, 2004.